Integral molecular announces preclinical P2X7 antibody assets for autoimmune disorders

January 09, 2020

PHILADELPHIA - Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces lead monoclonal antibodies (MAbs) against P2X7, a structurally complex ion channel that is the target for autoimmune disorders including atopic dermatitis and glomerulonephritis. The panel of P2X7 antibodies is fully humanized and optimized, and ready to progress towards preclinical studies.

The P2X7 ion channel target is involved in regulating a population of T cells that drive multiple autoimmune diseases. However, the target has been largely refractory to antibody discovery efforts due to its complex structure.

"Despite its important role in the pathway of many diseases, there are no existing drugs against P2X7," said Ross Chambers, VP of Antibody Discovery. "Our MPS Antibody Discovery platform was built to handle complex membrane protein targets such as P2X7 and has enabled us to isolate high-affinity antibodies in the picomolar range that exhibit antagonist or rare agonist activity."

Integral Molecular's MPS Antibody Discovery platform encompasses a comprehensive technology suite that overcomes the obstacles of working with highly conserved and structurally complex membrane protein targets, including antigen engineering and presentation on Lipoparticles, immunization of divergent species, and deep screening techniques such as B-cell cloning to recover rare antibodies.

Integral Molecular will discuss its antibody assets in immune modulation, oncology, and metabolic disease at the upcoming JP Morgan Conference taking place from January 13-16, 2020 in San Francisco, California. The company is currently isolating MAbs against dozens of membrane protein targets and welcomes antibody out licensing opportunities and discovery partnerships.
-end-
About Integral Molecular

Integral Molecular is the industry leader in epitope mapping and antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company's extensive experience optimizing membrane proteins, Integral Molecular's technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases.

Integral Molecular

Related Diseases Articles from Brightsurf:

Understanding the spread of infectious diseases
Physicists at M√ľnster University (Germany) have shown in model simulations that the COVID-19 infection rates decrease significantly through social distancing.

Parkinson's disease is not one, but two diseases
Researchers around the world have been puzzled by the different symptoms and varied disease pathways of Parkinson's patients.

New gene implicated in neuron diseases
Healthy NEMF helps the cell recycle garbled protein fragments. But several mutant forms resulted in neuromuscular, neurodegenerative or other ALS-like disease, the scientists found.

Stretching your legs may help prevent diseases such as heart diseases and diabetes
New research published today in The Journal of Physiology shows that 12 weeks of easy-to-administer passive stretching helps improve blood flow by making it easier for your arteries to dilate and decreasing their stiffness.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

How many rare diseases are there?
Dr. Tudor Oprea says a better method for classifying rare diseases will lead to improved patient care.

A vaccine against chronic inflammatory diseases
In animals, a vaccine modifying the composition and function of the gut microbiota provides protection against the onset of chronic inflammatory bowel diseases and certain metabolic disorders, such as diabetes and obesity.

Ants fight plant diseases
New research from Aarhus University shows that ants inhibit at least 14 different plant diseases.

New, noninvasive test for bowel diseases
Gut diseases such as inflammatory bowel disease (IBD) are increasingly prevalent worldwide, especially in industrialized countries.

What is known -- and not known -- about heart muscle diseases in children
Cardiomyopathies (heart muscle diseases) in children are the focus of a new scientific statement from the American Heart Association that provides insight into the diagnosis and treatment of the diseases as well as identifying future research priorities.

Read More: Diseases News and Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.